Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force

An analysis of dose modifications for infants in 29 Children's Oncology Group protocols across 10 cancer types revealed 11 sets of criteria defining the infant population using age, weight, body surface area (BSA), or a combination of these parameters and eight dose modification methods. A new...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2017-11, Vol.64 (11), p.n/a
Main Authors: Balis, Frank M., Womer, Richard B., Berg, Stacey, Winick, Naomi, Adamson, Peter C., Fox, Elizabeth
Format: Article
Language:English
Subjects:
anticancer drugs
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - standards
Antineoplastic drugs
Antitumor agents
Banding
body surface area
Body weight
Cancer
Chemotherapy
Child, Preschool
Children
Children & youth
dose
Dose-Response Relationship, Drug
Drug dosages
Female
Hematology
Humans
Infant
Infant, Newborn
Infants
Male
Neoplasms - drug therapy
Neoplasms - pathology
Oncology
Parameter modification
Pediatrics
Practice Guidelines as Topic - standards
Prognosis
Standardization
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An analysis of dose modifications for infants in 29 Children's Oncology Group protocols across 10 cancer types revealed 11 sets of criteria defining the infant population using age, weight, body surface area (BSA), or a combination of these parameters and eight dose modification methods. A new method of dosing anticancer drugs in infants was developed based on the rationale that prior modifications were implemented to reduce toxicity, which is not cancer‐specific. The new method uses BSA dose banding in dosing tables for infants and children with a BSA
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.26636